Related Experiment Video
Updated: Jul 19, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
Ethyl-EPA in Alzheimer's disease--a pilot study
Paul F Boston1, Amanda Bennett, David F Horrobin
1Michael Carlisle Centre, Nether Edge Hospital, 75 Osborne Road, Sheffield, S. Yorks S11 9BF, UK. p.boston@shef.ac.uk
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|September 24, 2004
Summary
This pilot study found ethyl-eicosapentaenoate (ethyl-EPA) did not significantly improve cognition in Alzheimer's disease patients over 12 weeks. Longer studies may be needed to confirm any potential benefits of ethyl-EPA for Alzheimer's treatment.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Ethyl-eicosapentaenoate (ethyl-EPA), an omega-3 fatty acid, is being investigated for potential therapeutic effects in AD.
Purpose of the Study:
- To estimate the change in cognitive measures during a 12-week treatment period with ethyl-EPA in Alzheimer's disease patients.
- To assess the impact of ethyl-EPA on erythrocyte membrane fatty acids and overall functioning.
Main Methods:
- Pilot study with a simple linear design: 12-week baseline (no treatment) followed by 12-week ethyl-EPA treatment.
- Cognitive assessments and visual analogue ratings were conducted.
- Blood samples were analyzed for erythrocyte membrane fatty acids before and after treatment.
Main Results:
- No significant differences were observed in the rate of decline of cognitive efficacy measures between baseline and treatment periods.
- A minor improvement was noted in carer's visual analogue rating of overall functioning (P=0.02).
- Erythrocyte membrane fatty acid levels were measured post-treatment.
Conclusions:
- Ethyl-eicosapentaenoate (ethyl-EPA) is unlikely to have clinically significant effects on cognition in Alzheimer's disease within a 12-week period.
- Further research with extended treatment durations may be necessary to ascertain the efficacy of ethyl-EPA for Alzheimer's disease.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...